At Maze, we envision a world where genetic insights inspire new medicines. We will navigate the breadth of genetic information available to us to understand how genetic modifiers can provide protection against severe diseases.
By bringing together human genetics and functional genomics into a platform driven by scientific pioneers and experienced company builders, we will develop new medicines that change the course of diseases.
Ph.D., President, Chief Mazer
M.D., Ph.D., Chief Medical Officer
Ph.D., Chief Business Officer
M.D., Senior Vice President, Human Genetics
Ph.D., Senior Vice President, Drug Discovery
Senior Vice President, Human Resources
M.D., Ph.D., Vice President, R&D
Ph.D., Vice President, Data Science
Dr. Mark Daly is an institute member of the Broad Institute, co-director of the Program in Medical and Population Genetics and the director of the Institute for Molecular Medicine Finland. His research primarily focuses on the development and application of…
View full bioDr. Stephen Elledge is a world-renowned leader in the field of the genetics, biochemistry, genomics, and proteomics of cancer cell biology. He is currently the Gregor Mendel Professor of Genetics and Medicine at Harvard Medical School and Brigham and Women’s…
View full bioDr. Aaron Gitler is professor of genetics at Stanford University. One of his most pivotal discoveries was the identification of a major genetic contributor to amyotrophic lateral sclerosis (ALS). Aaron’s team recently demonstrated that inhibiting this gene markedly extends lifespan…
View full bioDr. Sek Kathiresan, a physician scientist and a human geneticist, is the CEO of Verve Therapeutics, Professor of Medicine (on leave) at Harvard Medical School, and Institute Member (on leave) at Broad Institute. Sek leverages human genetics to understand the…
View full bioDr. Jonathan Weissman is professor and vice chair of the Department of Cellular & Molecular Pharmacology at the University of California, San Francisco and an investigator of the Howard Hughes Medical Institute. He serves as the co-director of the Innovative…
View full bioDr. Charles Homcy is a partner at Third Rock Ventures, where he focuses on the formation of companies that discover and develop novel therapeutic approaches. He brings significant experience building and leading successful biotech companies and has played an integral…
View full bioDr. Brendan Bulik-Sullivan is a partner at GV focusing on life sciences investments. Before GV, Dr. Bulik-Sullivan worked on applied statistics and machine learning research in genetics and biotechnology. Dr. Bulik-Sullivan led machine learning at Gritstone Oncology, where he designed…
View full bioDr. Jason Coloma is the CEO of Maze Therapeutics. Prior to his appointment to CEO, he was Maze’s interim chief operating officer and a venture partner at Third Rock Ventures, where he was instrumental in the founding and launch of…
View full bioJonathan Lim, M.D., is the founder and managing partner at City Hill Ventures. In addition to his role at City Hill, Dr. Lim is a venture partner at ARCH Venture Partners, chairman, chief executive officer and co-founder at Erasca, and…
View full bioRobert Nelsen is a co-founder and a managing director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including 19 that have…
View full bioDr. Richard Scheller is the former head of therapeutics and chief scientific officer of 23andMe. Prior to his role there, he spent 14 years at Genentech where he was executive vice president of research and early development. He served on…
View full bioDr. Jeffrey Tong is a partner with Third Rock Ventures, where he focuses on drug discovery and development across the firm’s portfolio. He is chairman of Ambys Medicines, and also serves on the board of Nurix Therapeutics. Prior to joining…
View full bioEli Casdin founded Casdin Capital in 2011. For the last 16 years, he has analyzed and invested in disruptive technologies and business models in life sciences and healthcare. Prior to founding Casdin Capital, Eli was a vice president in at…
View full bioDr. Jeff Finer is a venture partner at Third Rock Ventures, where he focuses on drug discovery and development opportunities across the firm’s portfolio. Jeff brings to Maze more than 30 years of research and clinical experience, including 20 years…
View full bioDr. Michael Rome joined Foresite Capital in 2016 and is active in the firm’s public and private market investments. Michael has experience investing across diverse therapeutic areas and has board observer roles (past and present) at Turning Point Therapeutics, Arcus…
View full bio
Dr. Charles Homcy is a partner at Third Rock Ventures, where he focuses on the formation of companies that discover and develop novel therapeutic approaches. He brings significant experience building and leading successful biotech companies and has played an integral role in the launching and building of Third Rock Ventures’ portfolio companies, including Ambys Medicines, Global Blood Therapeutics, Pliant Therapeutics, Relay Therapeutics, Goldfinch Bio, CytomX and MyoKardia.